Published in final edited form as:

Arch Biochem Biophys. 2015 March 15; 570: 47–57. doi:10.1016/j.abb.2015.02.014.

Catalytic Activity of Human Indoleamine 2,3-Dioxygenase (*hIDO1*) at Low Oxygen

Ayodele O. Kolawole, Brian P. Hixon, Laura S. Dameron, Ian M. Chrisman, and Valeriy V. Smirnov*

Department of Chemistry and Biochemistry, Center for Biomolecular Structure and Dynamics, University of Montana, Missoula, MONTANA 59812

Abstract

A cytokine-inducible extrahepatic human indoleamine 2,3-dioxygenase (*hIDO1*) catalyzes the first step of the kynurenine pathway. Immunosuppressive activity of *hIDO1* in tumor cells weakens host T-cell immunity, contributing to the progression of cancer. Here we report on enzyme kinetics and catalytic mechanism of *hIDO1*, studied at varied levels of dioxygen (O_2) and L-tryptophan (L-Trp). Using a cytochrome b_5 -based activating system, we measured the initial rates of O_2 decay with a Clark-type oxygen electrode at physiologically-relevant levels of both substrates. Kinetics was also studied in the presence of two substrate analogs: 1-methyl-L-tryptophan and norharmane. Quantitative analysis supports a steady-state rather than a rapid equilibrium kinetic mechanism, where the rates of individual pathways, leading to a ternary complex, are significantly different, and the overall rate of catalysis depends on contributions of both routes. One path, where O_2 binds to ferrous *hIDO1* first, is faster than the second route, which starts with the binding of L-Trp. However, L-Trp complexation with free ferrous *hIDO1* is more rapid than that of O_2 . As the level of L-Trp increases, the slower route becomes a significant contributor to the overall rate, resulting in observed substrate inhibition.

Keywords

indoleamine dioxygenase; oxygen electrode; enzyme kinetics; substrate analog; inhibition; global fit

© 2015 Published by Elsevier Inc.

*Corresponding Author Valeriy V. Smirnov, (406) 243-6470, valeriy.smirnov@umontana.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supporting Information. Figures showing representative O_2 depletion traces recorded on a Clark-type oxygen electrode (Figure S1), optical absorption spectra for NHM binding to *hIDO1* (Figure S2) with results of the fit (Figure S3), Cornish-Bowden plots for inhibition of *hIDO1* with NHM and 1-Me-L-Trp versus varied O_2 at fixed L-Trp (Figure S4), complete reference 9, and the derivation of kinetic expressions, used for modeling $^{Trp}k_{cat}/K_M$ and $^{O_2}k_{cat}/K_M$ ratios and initial rates of O_2 consumption. This material is available free of charge via the Internet.

Introduction

In the human body, L-tryptophan (L-Trp) is one of the nine essential dietary amino acids.¹ It functions as a building block of proteins and as a precursor of niacin, an intermediate in the biosynthesis of NAD⁺,² and serotonin, a mood-modulating neurotransmitter and physiological regulator.³ Up to 90% of dietary L-Trp is catabolized via the kynurenine pathway.^{4,5} The kynurenine pathway starts with a dioxygenation reaction of L-Trp that is catalyzed by indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO).^{6,7} Both IDO and TDO contain a type-*b* heme and use dioxygen (O₂) to open the five-membered ring of L-Trp to form N-formyl-L-kynurenine (NFK), as shown in Scheme 1.⁶ Excessive exhaustion of L-Trp via the kynurenine pathway significantly hinders T-cell proliferation, differentiation, effector function, and viability, resulting in a suppressed immune response.⁸ Catabolites of L-Trp are capable of promoting immunosuppression and tumor tolerance during cancer,⁹ formation of cataracts,^{10,11} HIV-related neurological damage, and ischemic brain injury.¹²

IDO is induced extrahepatically throughout the body.⁶ The strongest inducer of IDO is a proinflammatory cytokine interferon- γ (IFN- γ).¹³ IDO-initiated L-Trp degradation accelerates during conditions that cause cellular activation of the immune response such as malignancy, inflammation, autoimmune disorder, and pregnancy.¹² The induction of IDO by IFN- γ is greatly diminished in a hypoxic environment, where the O₂ concentration is between 5% and 10% of air-saturation level.^{14,15,16} During hypoxia, cells stimulated with IFN- γ demonstrate reduced levels of IDO compared to normoxic conditions. IDO antimicrobial and immunoregulatory functions are also significantly impaired.^{14,15,16}

Even under normoxic conditions, the physiological levels of O₂ are quite low (between 14% and 24% of air-saturation level or between ~35 μ M and ~65 μ M O₂).¹⁷ The steady-state kinetic data for IDO are known primarily in solutions saturated with air.^{18,19,20,21,22,23,24,25,26,27,28} Here, we report on enzyme kinetic studies of human IDO isoform-1 (*h*IDO1) (EC 1.13.11.52) at physiologically-relevant levels of O₂ as a function of both substrates – O₂ and L-Trp. This information is vital for understanding enzyme-substrate interactions in *h*IDO1 and for designing inhibitors with enhanced therapeutic responses.^{29,30,31} Using a new assay methodology, we quantify the effects of O₂ concentration on the initial rates of *h*IDO1 catalysis. We analyze the data within a mechanistic model that allows for initial complexation of either O₂ or L-Trp with a free ferrous form of *h*IDO1 – Fe(II)*h*IDO1.^{6,23} This model also considers that both resulting substrate-bound species – Fe(III)*h*IDO1•O₂^{•-} and Fe(II)*h*IDO1•L-Trp,³² lead to a ternary complex – *h*IDO1•O₂•L-Trp.

The ternary complex has been previously characterized in human and rabbit IDO by the stepwise mixing of substrates with the ferrous enzyme either manually, at a low temperature, or on a stopped-flow, at room temperature.^{24,25,26,27,28,33,34} Here we analyze the kinetics of the formation of the ternary complex. We observe that under steady-state conditions, the ternary complex forms via two separate pathways. Even though the O₂-first/L-Trp-second addition route is faster than the L-Trp-first/O₂-second path,^{23,35} the organic substrate binds to the free ferrous *h*IDO1 at a higher rate than O₂.³⁵ At low physiologically-relevant

concentrations of both substrates, the slower L-Trp-initiated pathway is a significant contributor to the overall catalytic rate, resulting in pronounced substrate inhibition of catalysis. Such kinetic control of *hIDO1* activity could be operational *in vivo* where, depending on tissue oxygenation,¹⁷ O₂ supply may be limited relative to L-Trp level.^{36,37}

Materials and Methods

Reagents

L-tryptophan (Cat. # T0254), β -NADH (Cat. # N1161), Cu,Zn-SOD (Cat. # S8160), catalase (Cat. # C100), lysozyme (Cat. # L6876), DNase I (Cat. # D5025), PMSF (Cat. # P7626), Trizma (Cat. # T1503), MOPS (Cat. # M3183), imidazole (Cat. # 56750), EDTA (Cat. # ED4SS), kanamycin sulfate (Cat. # K1377), 1-methyl-L-tryptophan (Cat. # 447439), norharmane (Cat. # N6252) and norharmane hydrochloride (Cat. # N6377) were from Sigma-Aldrich; agar (Cat. # N833) and yeast extract (Cat. # J850) were from Amresco; tryptone (Cat. # 95039) was from Fluka; sodium chloride (Cat. # SX0425), monobasic sodium phosphate (Cat. # SX0710), dibasic sodium phosphate (Cat. # SX0715) were from EMD; δ -aminolevulinic acid hydrochloride (Cat. # 01433) and IPTG (Cat. # 00194) were from Chem-Impex International, Inc. in Wood Dale, IL; N₂ (pre-purified grade) and O₂ (USP grade) were from Norco, Inc. in Boise, ID. The pETevIDO plasmid for *hIDO1* expression and the plasmids for cytochrome *b₅* and cytochrome *b₅* reductase were kindly provided by Prof. A. Grant Mauk (University of British Columbia).

Enzyme preparation

hIDO1 (EC 1.13.11.52) was overexpressed in One Shot BL21 Star (DE3) chemically competent *E. coli* cells (Invitrogen) using a published procedure.³⁸ Greater than 95% homogeneity of *hIDO1* was confirmed by the SDS-PAGE after the second Ni-affinity column and dialysis into 50 mM Tris•HCl pH 8.0 buffer, containing 100 mM NaCl and 4 mM EDTA. The purified enzyme exhibited an $[M+H]^+$ peak at $m/z = 45,586$ on a Microflex LRF MALDI-TOF mass spectrometer (Bruker), which is in good agreement with the expected value of $m/z = 45,643$. Cytochrome *b₅* and cytochrome *b₅* reductase, overexpressed in One Shot BL21 Star (DE3) cells, were purified as described elsewhere.^{39,40} The homogeneity of these proteins was confirmed by 10% SDS-PAGE analysis. Protein concentrations were determined spectrophotometrically. All enzyme stocks were stored at -75°C .

Measurement of initial rates of *hIDO1* catalysis by monitoring O₂ consumption

Initial rates of *hIDO1* catalysis of L-Trp dioxygenation were measured at 25.0°C using a Clark-type oxygen electrode consisting of a digital ammeter (Biological Oxygen Monitor, model 5300A, Yellow Springs Instruments (YSI)) and a polarographic oxygen probe (5331A, YSI). Highly reproducible O₂ depletion traces (Figure S1)⁴¹ were recorded in a reaction chamber thermostated on a modified bath assembly (5301B, YSI) interfaced to a recirculating water bath (DC10, Thermo Scientific; K20, Haake). A VWR 10'' $\times$ 10'' professional stirrer was used to maintain the stirring rate at 700 rpm. O₂ and N₂ gases were metered using a Riteflow flow meter (PMR1-010976, Bel-Art Scienceware). This experimental setup allowed for precise control of temperature, stirring rate, and oxygen

level. The oxygen probe was calibrated daily to the dissolved oxygen in air-saturated water (resistivity $18.2 \text{ M}\Omega \times \text{cm}$) at normal pressure. Due to the elevation of Missoula, the 100% air-saturation level of pure water at 25.0°C corresponds to $[\text{O}_2] = 230 \text{ }\mu\text{M}$, which is lower than $[\text{O}_2] = 258 \text{ }\mu\text{M}$ at sea level.⁴² Solubility of O_2 was calculated using atmospheric pressure measured with a mercury manometer interfaced to a high-vacuum line (Chemglass). Atmospheric pressure at sea level was taken as 760 mm Hg .⁴²

A typical reaction mixture (3.000 mL) contained 20 mM MOPS buffer at $\text{pH } 7.0$, $150 \text{ }\mu\text{M}$ β -NADH, $1.0 \text{ }\mu\text{M}$ cytochrome b_5 , 140 nM cytochrome b_5 reductase, 54 nM Cu,Zn-SOD, 12 nM catalase, and varying concentrations of L-Trp.⁴³ The solution was equilibrated against air or a mixture of pure O_2 and N_2 , saturated with water vapor at atmospheric pressure by passing through a fritted gas washing bottle (Chemglass, Cat. # CG-1114-13). During inhibition studies, the reaction mixture was also supplemented with $3\text{--}15 \text{ }\mu\text{L}$ of inhibitor stock solution to the final inhibitor concentration of $1\text{--}5 \text{ }\mu\text{M}$. Inhibitor stocks (100 mL of 1.00 mM solution of either 1-methyl-L-tryptophan or norharmane hydrochloride) were prepared in 100 mM potassium phosphate buffer at $\text{pH } 7.0$. The reaction was initiated by injecting a $5\text{-}\mu\text{L}$ aliquot of *h*IDO1 stock ($\sim 120 \text{ }\mu\text{M}$) into a reaction chamber to an expected final concentration of $\sim 200 \text{ nM}$, using a gas-tight syringe (Hamilton). The exact concentrations of *h* IDO1 stock solutions were measured spectrophotometrically on an AVIV Model 14 Spectrophotometer (Aviv Biomedical), or a NanoDrop 2000 (Thermo Scientific) using molar absorptivity $\epsilon_{\lambda=404\text{nm}} = 172,000 \text{ M}^{-1} \text{ cm}^{-1}$.⁴⁴

Initial rates of O_2 consumption were measured in the range of the steepest $[\text{O}_2]$ decline (12 s long), normally $2\text{--}4 \text{ s}$ after injecting the ferric *h*IDO1. All measurements were performed in triplicate or greater. Readouts of the oxygen probe were transmitted to a PC workstation with a 1-Hz sampling rate. The slopes of the oxygen consumption traces were determined in Excel 2010 (Microsoft) and their absolute values were expressed in $\mu\text{M/s}$. These initial velocities of O_2 consumption were converted to specific activity of *h*IDO1 by dividing by the exact final micromolar enzyme concentration – $[\text{hIDO1}]_{\text{T}}$. All nonlinear fits of the data to Eq. 1, Eq. 2, and Eq. 3 were performed in KaleidaGraph 4.1 (Synergy Software).

Measurement of initial rates of *h*IDO1 catalysis by monitoring NFK appearance

The formation of NFK was continuously monitored by UV absorption at 321 nm using an Applied Photophysics SX-20 stopped-flow spectrophotometer with a thermostated drive-syringe compartment and fast kinetics observation cell (0.5 ms dead time, 0.2 cm optical path length). The instrument was interfaced to a computer workstation. The measurements were performed at air-saturation level of O_2 in 20 mM MOPS buffer at $\text{pH } 7.0$ and 25.0°C . To eliminate interference from absorption of β -NADH at 340 nm ($\epsilon = 6,220 \text{ M}^{-1} \text{ cm}^{-1}$)⁴⁵ during catalytic turnover, ascorbate/methylene blue reducing system was used instead of β -NADH/cytochrome b_5 reductase/cytochrome b_5 . Typical final reactant concentrations were 20 mM for ascorbate and $10 \text{ }\mu\text{M}$ for methylene blue; L-Trp was varied from $3 \text{ }\mu\text{M}$ to $5,000 \text{ }\mu\text{M}$; $[\text{hIDO1}]_{\text{T}} = 262 \text{ nM}$, and catalase was present at 100 U/ml . The reactions were initiated by combining ferric *h*IDO1 from one syringe of the stopped-flow instrument with the substrate/reductant mixture from the second syringe. Individual reactions were monitored for 50 s . Initial velocities of NFK formation (in $\mu\text{M/s}$) were determined in the range of the

steepest linear increase of absorbance (~5 s long) at 321 nm ($\epsilon_{\text{NFK}} = 3,750 \text{ M}^{-1} \text{ cm}^{-1}$),⁴⁶ typically 2-4 s after mixing. Initial velocities were converted to specific activity of *hIDO1* by dividing by micromolar [*hIDO1*]_T. The slopes and standard deviations were determined in Excel 2010 (Microsoft). All nonlinear fits of the data, shown in Fig. 1 by blue diamonds, were done in KaleidaGraph 4.1 (Synergy Software).

Results

Activity assay for *hIDO1*, based on O₂ consumption

Isolated *hIDO1* exists in a ferric form and is inactive towards L-Trp dioxygenation. Ascorbate/methylene blue is a common activating system that reduces *hIDO1* to a ferrous state.^{22,23,24,25,26,27,28} Using these cofactors, the rate of NFK appearance can be monitored by absorption spectroscopy at 321 nm. Even though a single *hIDO1* turnover is electroneutral, the presence of reductant is necessary to maintain the enzyme in its active ferrous form by outcompeting a facile *hIDO1* autoxidation.³⁸ The ascorbate/methylene blue system performs well in air-saturated buffers;²⁰ however, at low O₂, significant oxygen consumption by the cofactors themselves⁴⁷ creates challenges for quantifying the effects of O₂ concentration on *hIDO1* kinetics.^{26,47}

In order to avoid unproductive O₂ depletion, we employed a combination of cytochrome *b*₅ and cytochrome *b*₅ reductase for *in situ* activation of ferric *hIDO1* with β -NADH.⁴³ Cu,Zn-SOD and catalase were also included in the assay mixture to eliminate trace amounts of possible byproducts of oxygen reduction: superoxide anion (O₂^{•-}) and hydrogen peroxide (H₂O₂). It was proposed in the literature that cytochrome *b*₅ is an endogenous reductant for ferric *hIDO1* *in vivo*.^{48,49} Reducing systems, that include cytochrome *b*₅ and either cytochrome *b*₅ reductase and β -NADH or cytochrome P450 reductase and β -NADPH, have been previously utilized for *in vitro* activation of *hIDO1*.^{33,50,51}

The initial rates of *hIDO1* catalysis were determined at 25.0 °C in 20 mM MOPS buffer at pH 7.0 by continuous monitoring of O₂ levels with a Clark-type oxygen electrode. Representative O₂ concentration profiles obtained by this oxygen depletion-based assay are shown in Figure S1 in the Supporting Information.⁴¹ Individual experiments were conducted for 60–80 s. During this time, the reactions reached completion by exhausting either L-Trp or O₂. When reactions were limited by L-Trp, the O₂ consumption levels reached $92 \pm 6\%$ of a theoretical value based on the 1:1 stoichiometric relationship between L-Trp and O₂ (Scheme 1). Stable O₂ levels in the thermostated reaction chamber, recorded either prior to injection of ferric *hIDO1* or upon reaction completion (as shown in Figure S1 A),⁴¹ indicated insignificant O₂ disappearance in the absence of the enzyme and/or substrate and suggested that the extent of O₂-consuming side reactions in the assay mixture was negligible. When O₂ was a limiting reactant, its concentration dropped to near zero within 80 s (Figure S1 B),⁴¹ indicating that *hIDO1* maintained activity even at extremely low O₂. At elevated levels of L-Trp, O₂ disappearance was observable for minutes after the injection of *hIDO1*, until anaerobic conditions were reached in the reaction chamber (Figure S1 C).⁴¹ The rates of O₂ consumption were directly proportional to [*hIDO1*]_T in the nM range of enzyme concentrations.

Since the postulated $O_2^{\bullet-}$ byproduct of *h*IDO1 autoxidation^{6,38} could interfere with the rate of O_2 depletion (because of a very rapid dismutation by Cu,Zn-SOD that regenerates 0.5 moles of O_2 per 1.0 mole of $O_2^{\bullet-}$), we further validated the suitability of O_2 consumption-based protocol for studies of effects of O_2 concentration on *h*IDO1 catalysis. We compared the steady-state kinetic parameters obtained on a Clark-type oxygen electrode with those found via monitoring the appearance of NFK by stopped-flow techniques. We used a kinetic model, shown in Scheme 2, adapted from the published literature.^{6,23}

In Scheme 2, the reductive activation of the enzyme and two autoxidation steps (that deactivate *h*IDO1) are indicated by the light blue arrows. The catalytic steps are shown in black. The reduction of *h*IDO1 is very rapid. Upon injection of inactive ferric *h*IDO1, the enzyme is activated and steady-state is reached in 2-4 s, which is comparable to pre-steady-state kinetics of a fully reduced enzyme.²⁶ This allows us to write the material balance for the total concentration of *h*IDO1 during a steady-state catalytic turnover, supported by both reducing systems, as a sum of four catalytically-active forms, shown in Scheme 2 in black. These forms include a ternary complex – *h*IDO1• $O_2^{\bullet-}$ •L-Trp, two binary complexes – $Fe(III)hIDO1 \cdot O_2^{\bullet-}$ and $Fe(II)hIDO1 \cdot L-Trp$, and a free enzyme – $Fe(II)hIDO1$. The half-life ($t_{1/2}$) of the binary $Fe(III)hIDO1 \cdot O_2^{\bullet-}$ complex in 20 mM MOPS at pH 7.0 and 20 °C, is ~100 s, indicating that this form undergoes autoxidation with $k_{-auto} = 0.006 s^{-1}$ (Scheme 2).³⁸ The rate constant for autoxidation of the ternary complex under the same conditions is significantly larger: $k''_{auto} = 0.17(2) s^{-1}$ (Scheme 2).³⁸ However, as we show below, these processes do not significantly affect the steady-state kinetic parameters obtained by monitoring O_2 depletion.

Kinetics of *h*IDO1 in air-saturated buffer

In Fig. 1, the results of our O_2 consumption-based kinetic studies (red circles) are compared with those obtained by monitoring the appearance of NFK (blue diamonds).

Using the O_2 consumption-based assay at constant initial $[O_2] = 230 \mu M$ and $[hIDO1]_T = 219 nM$, rates were studied as a function of $[L-Trp]$. Substrate inhibition was observed as $[L-Trp]$ was elevated from 3 μM to 400 μM (Fig. 1 A, red circles).^{22,23} The data were fitted to Eq. 1, giving $^{Trp}k_{cat} = 8.2 \pm 0.3 s^{-1}$, $^{Trp}K_M = 19 \pm 2 \mu M$, and $^{Trp}K_{SI} = 296 \pm 34 \mu M$.

$$\text{Initial Rate} = \frac{-\frac{d[O_2]}{dt}}{[hIDO1]_T} = \frac{^{Trp}k_{cat} [L - Trp]}{^{Trp}K_M + [L - Trp] \left(1 + \frac{[L-Trp]}{^{Trp}K_{SI}}\right)} \quad (1)$$

Here, $^{Trp}k_{cat}$, $^{Trp}K_M$, and $^{Trp}K_{SI}$ are the apparent rate, Michaelis, and substrate inhibition constants, respectively; $[L-Trp]$ is the concentration of varied inhibitory substrate: L-Trp.⁵²

Eq. 1 differs from the Michaelis-Menten equation by the presence of $\left(1 + \frac{[L-Trp]}{^{Trp}K_{SI}}\right)$ term in the denominator. When $[L-Trp] \gg ^{Trp}K_{SI}$, this term dominates, reducing the right-hand side of

Eq. 1 to $\frac{^{Trp}K_{SI}}{[L-Trp]} \times ^{Trp}K_{cat}$. This demonstrates that the enzyme activity approaches zero as $[L-Trp]$ is increased significantly above the $^{Trp}K_{SI}$. Eq. 1 is generally applicable to cases of complete substrate inhibition where continued growth in substrate concentration ultimately

halts catalysis, causing characteristic non-hyperbolic behavior with a maximum rate

observed at $[L - Trp] = \sqrt{TrpK_M \times TrpK_{SI}}$.⁵²

Further increase in [L-Trp] beyond 400 μM suggests that observed substrate inhibition is partial rather than complete because initial rates appear to approach a plateau region at high [L-Trp] (Fig. 1 **B**, red circles). Partial substrate inhibition often results from modifications of the catalytic pathway, rather than a complete loss of enzyme activity. Instead of Eq. 1, Eq. 2 is more suitable for fitting the data in cases of partial substrate inhibition.⁵³ Fitting the data, shown by red circles in Fig. 1 **B**, to Eq. 2 gives $Trpk_{cat} = 8.3 \pm 0.5 \text{ s}^{-1}$, $TrpK_M = 19.0 \pm 2.7 \mu\text{M}$, $TrpK_{SI} = 200 \pm 42 \mu\text{M}$, and $TrpK'_{SI} = 1066 \pm 250 \mu\text{M}$.

$$\text{Initial Rate} = \frac{-\frac{d[\text{O}_2]}{dt}}{[hIDO1]_T} = \frac{Trpk_{cat} [L - Trp] \left(1 + \frac{[L - Trp]}{TrpK'_{SI}}\right)}{TrpK_M + [L - Trp] \left(1 + \frac{[L - Trp]}{TrpK_{SI}}\right)} \quad (2)$$

Here, $Trpk_{cat}$, $TrpK_M$, $TrpK_{SI}$ and [L-Trp] have the same meaning as in Eq. 1, and $TrpK'_{SI}$ is another apparent substrate inhibition constant. If the value of $TrpK'_{SI}$ is very large and $TrpK'_{SI} \gg TrpK_{SI}$, Eq. 2 reduces to Eq. 1, and the best fits of the data to Eq. 2 and Eq. 1 become indistinguishable. Compared to Eq. 1, the numerator of Eq. 2 contains an extra term:

$\left(1 + \frac{[L - Trp]}{TrpK_{SI}}\right)$. At high [L-Trp], the presence of this term reduces Eq. 2 to Initial

Rate $= \frac{TrpK_{SI}}{TrpK'_{SI}} k_{cat}$, giving a constant non-zero value for the initial rate at high substrate concentration, hence the plateau region in Fig. 1 **B**. The exact mathematical equations for expression of $Trpk_{cat}$, $TrpK_M$, $TrpK_{SI}$, and $TrpK'_{SI}$ (in terms of fixed $[\text{O}_2]$ and the rate constants for each elementary step) are dependent on the kinetic model under consideration. For the kinetic model used in our study (see Scheme 2), derivation of these expressions is shown in the Supporting Information.⁴¹

Fitting the data, shown in Fig. 1 **A** by the blue diamonds, to Eq. 1 gives $Trpk_{cat} = 8.7 \pm 1.3 \text{ s}^{-1}$, $TrpK_M = 28 \pm 8 \mu\text{M}$, and $TrpK_{SI} = 266 \pm 87 \mu\text{M}$. These steady-state kinetic parameters, obtained by monitoring formation of NFK (Fig. 1), demonstrate similar dependence on the pH that was established for the rabbit enzyme.^{18,19} It was previously reported that at pH 6.5 catalytic activity of *hIDO1* is six times greater than at pH 8.0.³³ At pH 8.0,²³ $Trpk_{cat}$ was found to be $1.4 \pm 0.1 \text{ s}^{-1}$ and, at pH 7.4,²² $Trpk_{cat}$ was determined to be $3.1 \pm 0.2 \text{ s}^{-1}$. Thus, the value of $Trpk_{cat} = 8.3 \text{ s}^{-1}$, reported here, may indicate that *hIDO1* activity reaches a maximum at slightly acidic pH (between pH 6.5 and 7.0). The magnitudes of two other kinetic constants – $TrpK_M$ and $TrpK_{SI}$, also increase with decreasing pH. The Michaelis constant changes from $5.0 \pm 0.3 \mu\text{M}$ at pH 8.0 to $15 \pm 2 \mu\text{M}$ at pH 7.4 and $\sim 30 \mu\text{M}$ at pH 7.0, while the substrate inhibition constant jumps from $65 \pm 6 \mu\text{M}$ at pH 8.0 to $170 \pm 20 \mu\text{M}$ at pH 7.4 and $\sim 250 \mu\text{M}$ at pH 7.0.^{22,23}

Fitting the data to Eq. 2, using the full range of L-Trp concentrations used in NFK-forming assays (Fig. 1 **B**, blue diamonds), gives similar results to those obtained earlier by fitting the data in Fig. 1 **A** (blue diamonds) to Eq. 1: $Trpk_{cat} = 8.9 \pm 1.4 \text{ s}^{-1}$, $TrpK_M = 29 \pm 9 \mu\text{M}$, $TrpK_{SI} = 174 \pm 68 \mu\text{M}$, and $TrpK'_{SI} = 1028 \pm 409 \mu\text{M}$. Comparison of the steady-state kinetic

parameters, obtained by monitoring depletion of O₂ with those obtained by observing the appearance of NFK, shows close agreement between these two assays. Within experimental error, the steady-state kinetic parameters are identical.

Steady-state kinetics of hIDO1 at low O₂

We examined steady-state kinetics of hIDO1 by monitoring O₂ depletion. The concentration of one substrate was varied, while the second substrate was held constant at several sub-saturation levels.⁵⁴ From our saturation kinetics studies described above, the near-maximum activity of hIDO1 was observed at ~50 μM L-Trp and ~230 μM O₂. Treating O₂ as a fixed substrate, we systematically lowered its initial concentration, measuring rates of hIDO1 catalysis for each level as a function of [L-Trp]. In these experiments, [L-Trp] was varied from 8.33 μM to 50.0 μM at six fixed levels of O₂ from 34.5 μM to 230 μM (Fig. 2 A). Similarly, in a separate set of experiments, [O₂] was varied from 11.5 μM to 230 μM at six fixed levels of L-Trp between 8.33 μM and 50.0 μM (Fig. 2 B). For both substrates, these levels cover the physiological ranges of O₂ and L-Trp concentrations^{17,36,37} and bracket the values for apparent ^{Trp}*K_M* and ^{O₂}*K_M* that are near ~20 μM (Tables 1 and 2).

The best fit of the data in Fig. 2 A to Eq. 1 yields the steady-state kinetic parameters – ^{Trp}*k_{cat}*, ^{Trp}*K_M*, and ^{Trp}*K_{SI}*, which are shown in Table 1. The ^{Trp}*k_{cat}*/*K_M* ratios, calculated with errors propagated from uncertainties in the fitted values of ^{Trp}*k_{cat}* and ^{Trp}*K_M*, are also summarized in Table 1. These ratios represent an apparent second-order rate constant for the reaction of hIDO1 and L-Trp to form NFK, and provide a measure of enzyme catalytic efficiency for each fixed [O₂]. Similarly, the values of ^{O₂}*k_{cat}*, ^{O₂}*K_M*, and ^{O₂}*K_{SI}*, obtained by the best fit of the data in Fig. 2 B to Eq. 3, are given in Table 2 together with the calculated ^{O₂}*k_{cat}*/*K_M* ratios. In this case, the ^{O₂}*k_{cat}*/*K_M* ratios correspond to an apparent second-order rate constant for the reaction of hIDO1 with O₂ to form NFK at each fixed level of L-Trp. The uncertainty in the magnitude of ^{O₂}*k_{cat}*/*K_M* is significantly smaller than that of ^{Trp}*k_{cat}*/*K_M*, which is a consequence of smaller experimental errors in both ^{O₂}*k_{cat}* and ^{O₂}*K_M*, compared to the errors in ^{Trp}*k_{cat}* and ^{Trp}*K_M*.

$$\text{Initial Rate} = \frac{-\frac{d[\text{O}_2]}{dt}}{[\text{hIDO1}]_T} = \frac{{}^{\text{O}_2}k_{cat} [\text{O}_2]}{{}^{\text{O}_2}K_M + [\text{O}_2] \left(1 + \frac{[\text{O}_2]}{{}^{\text{O}_2}K_{SI}}\right)} \quad (3)$$

Here, ^{O₂}*k_{cat}*, ^{O₂}*K_M*, and ^{O₂}*K_{SI}* are the apparent rate, Michaelis, and substrate inhibition constants, respectively; [O₂] is the concentration of varied inhibitory substrate – O₂. Eq. 3 is identical to Eq. 1, except here the roles of the substrates are switched and substrate inhibition is observed with varied O₂ at fixed L-Trp.⁵²

Varying [O₂] at constant [L-Trp] = 50.0 μM (the value that gives near-maximum velocity at air-saturation) results in typical saturation kinetics (Fig. 2 B) with ^{O₂}*k* = 5.8 ± 0.1 s⁻¹ and ^{O₂}*K_M* = 18.6 ± 0.6 μM. This value of ^{O₂}*K_M* is lower than a typical physiological level of O₂ in tissues, which ranges from ~35 μM to ~65 μM.¹⁷ It is also somewhat lower than that reported at pH 7.4 (^{O₂}*K_M* = 42 μM)²² or estimated at pH 8.0 (^{O₂}*K_M* < 50 μM).²⁶

The dependence of $\text{Varied } k_{\text{cat}}/K_M$ for varied substrate on the concentration of fixed substrate signals sequential addition of O_2 and L-Trp to *h*IDO1 (Fig. 3). A straight line in a double reciprocal plot, such as $1/(\text{Initial Rate})$ vs. $1/[\text{Varied}]$, has a slope that is a reciprocal of $\text{Varied } k_{\text{cat}}/K_M$. Thus, independence of $\text{Varied } k_{\text{cat}}/K_M$ on the level of fixed substrate is algebraically equivalent to a set of parallel lines in the double reciprocal plot, which is indicative of a ping-pong mechanism.⁵² Therefore, seeing an increase in the value of $\text{O}_2 k_{\text{cat}}/K_M$ with rising concentration of L-Trp (Fig. 3, blue diamonds) favors a sequential kinetic mechanism. This mechanism requires the presence of both substrates in the catalytic site of *h*IDO1 before NFK can be formed and released. Furthermore, since the sequential entry of substrates into the catalytic cycle also requires a reversible process, which links the two substrate-bound enzyme forms, binding of the first substrate to *h*IDO1 must be reversible. The values of $\text{Trp } k_{\text{cat}}/K_M$ appear to be independent of the concentration of fixed O_2 substrate (Fig. 3, red); this, however, does not rule out the mechanism depicted in Scheme 2. As can be seen from our modeling results, shown by solid and dashed lines in Fig. 3, the $\text{Trp } k_{\text{cat}}/K_M$ is expected to either be a constant (dashed line) or rapidly ascend to a plateau region with rising O_2 (solid line), depending on the kinetic model. The details of modeling studies are discussed below.

Modeling the dependence of $\text{Varied } k_{\text{cat}}/K_M$ on concentrations of fixed substrate

The availability of the individual rate constants (shown in the catalytic portion of Scheme 2), in the published literature and current study, allows for the modeling of $\text{Varied } k_{\text{cat}}/K_M$ ratios, whose experimental values are given in Tables 1 and 2. Raven and co-workers measured previously unreported rate constants for binding and dissociation of O_2 to and from ferrous *h*IDO1: $k_1 = (5.3 \pm 0.06) \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ and $k_{-1} = 6.8 \pm 1.8 \text{ s}^{-1}$ (Scheme 2).²⁶ Very recently, Nienhaus and co-workers determined a unimolecular rate constant for dissociation of L-Trp from a complex of ferrous *h*IDO1 with carbon monoxide and L-Trp, abbreviated here as $\text{Fe(II)}h\text{IDO1}\cdot\text{CO}\cdot\text{L-Trp}$.³⁵ The authors used the value of the constant as an estimate for the dissociation constant of L-Trp from $\text{Fe(II)}h\text{IDO1}\cdot\text{L-Trp}$ complex, $k_{-2} = 501 \pm 10 \text{ s}^{-1}$ (Scheme 2).³⁵ They also calculated the value of k_2 as $1.25 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ from k_{-2} and $\text{Trp } K_d = 400 \pm 70 \text{ }\mu\text{M}$ ⁵⁵ (an equilibrium constant for dissociation of L-Trp from $\text{Fe(II)}h\text{IDO1}\cdot\text{L-Trp}$). The magnitude of k_3 (Scheme 2) can be estimated from $\text{Trp } k_{\text{cat}}/K_M$ ratio measured at a high level of O_2 , where $k_1[\text{O}_2] \gg k_{-1}$. It can be seen from Scheme 2 that a high level of oxygen makes the first step (addition of O_2 to ferrous *h*IDO1) kinetically irreversible with $k_{-1} = 0$, reducing Eq. 6 (shown below) to $\text{Trp } k_{\text{cat}}/K_M = k_3$.^{23,56} From the fit of the data, obtained at air saturation ($[\text{O}_2] = 230 \text{ }\mu\text{M}$) and displayed as red circles in Fig. 1 **B**, to Eq. 2, we obtained $\text{Trp } k_{\text{cat}} = 8.3 \pm 0.5 \text{ s}^{-1}$ and $\text{Trp } K_M = 19.0 \pm 2.7 \text{ }\mu\text{M}$. The ratio of these constants gives the value of $k_3 = (4.37 \pm 0.74) \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$, which is in agreement with the $k_{\text{on}} = (1.2 \pm 0.1) \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ reported by Yeh and co-workers for the binding of L-Trp to a complex of ferric *h*IDO1 with cyanide anion – $\text{Fe(III)}h\text{IDO1}\cdot\text{CN}^-$, which authors used as a mimic of the ferrous *h*IDO1 adduct with O_2 – $\text{Fe(III)}h\text{IDO1}\cdot\text{O}_2^{\bullet-}$.⁵⁵ Using stopped-flow to monitor absorbance at 570 nm, Raven and co-workers measured the rate of oxygen binding to ferrous *h*IDO1 in the presence of L-Trp, $k_4 = (1.6 \pm 0.2) \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ (Scheme 2).²³ The value of k_5 can be approximated by $\text{Trp } k_{\text{cat}}$, measured at high O_2 . Similarly to Eq. 6, Eq. 4 can be greatly simplified when $k_1[\text{O}_2] \gg k_{-1}$. In this case, k_{-1} is effectively zero, and Eq. 4 reduces to $\text{Trp } k_{\text{cat}} = k_5$; thus, $k_5 = 8.3 \pm 0.5 \text{ s}^{-1}$.⁵⁷ Using these values of the rate constants, we

calculated the magnitude of $^{Trp}k_{cat}$, $^{Trp}K_M$, and $^{Trp}k_{cat}/K_M$ (Table 3) and $^{O_2}k_{cat}$, $^{O_2}K_M$, and $^{O_2}k_{cat}/K_M$ (Table 4) for several levels of fixed substrate, using Eq. 4, 5, 6, 7, 8 and 9, respectively.⁵⁸ The calculated values of $^{Trp}k_{cat}/K_M$ and $^{O_2}k_{cat}/K_M$ are plotted in Fig. 3 as solid lines. The results of modeling predict that the $^{Varied}k_{cat}/K_M$ ratio is dependent on the level of fixed substrate, characteristic of a sequential kinetic mechanism.⁵² Good agreement between the experimental and computed values (Fig. 3) offers support for the use of the catalytic cycle, depicted in Scheme 2, for describing the kinetic mechanism of *hIDO1*.

$$^{Trp}k_{cat} = \frac{k_4 [O_2] + k_{-2} + \frac{\alpha}{\beta} k_{-1}}{\left(\frac{1}{k_1 [O_2]} + \frac{1}{k_5} \right) \left(k_4 [O_2] + k_{-2} + \frac{\alpha}{\beta} k_{-1} \right) + \frac{1-\alpha}{\beta} \times \frac{k_{-1}}{k_1 [O_2]}} \quad (4)$$

$$^{Trp}K_M = \frac{\frac{1}{k_5} (k_4 [O_2] + k_{-2}) \left(1 + \frac{k_{-1}}{k_1 [O_2]} \right)}{\left(\frac{1}{k_1 [O_2]} + \frac{1}{k_5} \right) \left(k_4 [O_2] + k_{-2} + \frac{\alpha}{\beta} k_{-1} \right) + \frac{1-\alpha}{\beta} \times \frac{k_{-1}}{k_1 [O_2]}} \quad (5)$$

$$^{Trp}k_{cat}/K_M = \frac{^{Trp}k_{cat}}{^{Trp}K_M} = \frac{k_3 \left(k_4 [O_2] + k_{-2} + \frac{\alpha}{\beta} k_{-1} \right)}{(k_4 [O_2] + k_{-2}) \left(1 + \frac{k_{-1}}{k_1 [O_2]} \right)} \quad (6)$$

$$^{O_2}k_{cat} = \frac{\alpha k_2 [L - Trp] + k_{-2} + \frac{\alpha}{\beta} k_{-1}}{\left(\frac{1}{k_3 [L - Trp]} + \frac{1}{k_5} \right) \left(\alpha k_2 [L - Trp] + k_{-2} + \frac{\alpha}{\beta} k_{-1} \right) + \alpha \left(1 - \frac{1}{\beta} \right)} \quad (7)$$

$$^{O_2}K_M = \frac{\frac{1}{k_5} (k_2 [L - Trp] + k_{-2}) \left(1 + \frac{k_{-1}}{k_3 [L - Trp]} \right)}{\left(\frac{1}{k_3 [L - Trp]} + \frac{1}{k_5} \right) \left(\alpha k_2 [L - Trp] + k_{-2} + \frac{\alpha}{\beta} k_{-1} \right) + \alpha \left(1 - \frac{1}{\beta} \right)} \quad (8)$$

$$^{O_2}k_{cat}/K_M = \frac{^{O_2}k_{cat}}{^{O_2}K_M} = \frac{k_1 \left(\alpha k_2 [L - Trp] + k_{-2} + \frac{\alpha}{\beta} k_{-1} \right)}{(k_2 [L - Trp] + k_{-2}) \left(1 + \frac{k_{-1}}{k_3 [L - Trp]} \right)} \quad (9)$$

Here, k_1 , k_{-1} , k_2 , k_{-2} , k_3 , k_4 , and k_5 are the individual rate constants (Scheme 2); $= k_4/k_1$ and $\beta = k_3/k_2$. $[O_2]$ and $[L-Trp]$ are the initial concentrations of substrates.

The dashed lines in Fig. 3 show the results of modeling the $^{Trp}k_{cat}/K_M$ (red) and $^{O_2}k_{cat}/K_M$ (blue) ratios, assuming that the addition of O_2 to free $^{Fe(II)}hIDO1$ is irreversible with $k_{-1} = 0 \text{ s}^{-1}$ (Scheme 2).²³ Such an assumption is most valid at high O_2 , where $k_1 [O_2] \gg k_{-1}$ and the dashed and solid lines begin to merge (Fig. 3). However, at low O_2 , the reversibility of the first step is essential for accurate reproduction of experimental $^{O_2}k_{cat}/K_M$ ratios (Fig. 3, blue diamonds).

Kinetics of *hIDO1* in the presence of substrate analogs

To support the use of the kinetic model shown in Scheme 2 for describing the mechanism of catalytic dioxygenation of *L-Trp*, we studied the inhibition patterns in the presence of two

substrate analogs – 1-methyl-L-tryptophan (1-Me-L-Trp) and norharmane (NHM), shown in Scheme 3.

Using binding studies by means of optical absorption and CD spectroscopy, it was shown in the literature that 1-Me-L-Trp binds to the active site of IDO in a manner very similar to that of L-Trp.⁵⁹ In *h*IDO1, 1-Me-L-Trp is a competitive inhibitor versus L-Trp.^{22,60} When, however, 1-Me-L-Trp is the only indoleamine in the reaction mixture it is a very slow substrate for *h*IDO1.⁶⁰ Even though the dioxygenation of 1-Me-L-Trp is slow, its occurrence suggests that the binding of 1-Me-L-Trp to the catalytic site of *h*IDO1 does not completely impede the interactions that normally occur between O₂ and the enzyme, with the organic substrate bound near the heme moiety.

Sono demonstrated that in the rabbit enzyme, NHM is a noncompetitive inhibitor versus L-Trp.⁴⁷ The authors showed 1) that NHM binds to the ferrous catalytically-active form (by coordinating the heme iron center through the nitrogen atom of the pyridine moiety in NHM) with only a slightly negative cooperative effect on the binding of L-Trp and 2) that NHM directly competes with O₂ for the ferrous heme center.⁴⁷ We performed spectrophotometric titration of ferric *h*IDO1 with NHM to compare the inhibitor's binding in *h*IDO1 with that in the rabbit enzyme (Figures S2 and S3).⁴¹ Similarities in the optical changes upon titration of *h*IDO1 with NHM, and in the values of ^{NHM}*K*_d found for *h*IDO1 and the rabbit enzyme, indicate that NHM binding is identical for both human and rabbit enzymes (Figures S2 and S3).⁴¹

We used 1-Me-L-Trp and NHM as the analogs of L-Trp and O₂, respectively. According to the mechanism in Scheme 2, 1-Me-L-Trp is expected to bind to the free enzyme form and its binary complex with O₂ – ^{Fe(III)}*h*IDO1•O₂^{•-}, the same two forms that interact with L-Trp; while, NHM should be able to form complexes with both forms of *h*IDO1 that bind oxygen, the free enzyme and its binary complex with L-Trp – ^{Fe(II)}*h*IDO1•L-Trp. The inhibition patterns that could be expected for a particular bi-substrate mechanism were summarized by Fromm.⁶¹ Rules for predicting such patterns were developed by Cook and Cleland.⁶² For a sequential random mechanism, as the one shown in Scheme 2, which can be either rapid equilibrium or steady-state, the inhibition patterns are expected to be similar for both substrate analogs. A competitive inhibition pattern is expected when the varied substrate is a match for the substrate analog. A net noncompetitive pattern is predicted for the mismatching varied substrate.^{61,62}

Inhibition patterns for 1-Me-L-Trp and NHM were obtained at sub-saturating concentrations of fixed substrate to prevent any distortion due to *h*IDO1 saturation.⁶¹ At fixed O₂, L-Trp was varied from 10.0 to 23.3 μM and initial velocities were measured in the absence and presence of added substrate-analog inhibitors. Similar experiments were performed at constant L-Trp, where [O₂] was varied from 34.5 to 57.6 μM. With O₂ as a fixed substrate, its concentration was 46.1 μM; while with constant L-Trp, its level was kept at 16.7 μM. Double reciprocal plots (Fig. 4) show that 1-Me-L-Trp is a competitive inhibitor for L-Trp (*K*_i = 5.2 ± 0.3 μM) and a noncompetitive inhibitor for O₂ (*K*_i = 5.2 ± 0.8 μM), while NHM is a competitive inhibitor for O₂ (*K*_i = 12 ± 7 μM) and a noncompetitive inhibitor for L-Trp (*K*_i = 30 ± 16 μM). Replots of the data in Fig. 4 **C** and **D**, by the method of Cornish-

Bowden,⁶³ lead to unmistakable assignments of NHM as a competitive inhibitor versus O₂, and of 1-Me-L-Trp as a noncompetitive one versus O₂ (Figure S4).⁴¹

Fig. 4 illustrates that 1-Me-L-Trp, a competitive inhibitor versus L-Trp (Fig. 4 A), is a noncompetitive one versus O₂ (Fig. 4 C and also Figure S4 B). Furthermore, NHM, which is a competitive inhibitor versus varied O₂ (Fig. 4 D and also Figure S4 A), is also a noncompetitive inhibitor versus varied L-Trp (Fig. 4 B). Such a symmetric inhibition pattern, observed for both substrate analogs, validates the kinetic model used in our study (Scheme 2).^{61,62} For either an ordered or ping-pong kinetic mechanism, the inhibition pattern would have been uncompetitive for either one or both mismatching pairs of varied substrate/substrate analog, respectively.^{61,62}

Discussion

A typical total [L-Trp], comprising the free and albumin-bound forms, in the circulatory system of healthy blood donors is $73 \pm 15 \mu\text{M}$.³⁶ Tissue concentration of L-Trp measured in rats varies from ~20% (brain) to ~180% (liver) of the total L-Trp serum level.³⁷ If the tissue distribution of L-Trp in humans is similar, then the physiological levels of L-Trp are expected to vary from ~14 μM to ~130 μM . Maximum catalytic activity of *hIDO1* in air-saturated buffer is observed at [L-Trp] 73 μM (Fig. 1 A). As O₂ concentration drops to the levels of normal tissue oxygenation,¹⁷ the L-Trp concentration, which gives the maximum catalytic rate, appears to drop to $35 \pm 12 \mu\text{M}$ (Fig. 2 A, black line), suggesting that at physiological levels of both substrates, catalytic activity of *hIDO1* is modulated by L-Trp. In the following discussion we propose a kinetic mechanism for such modulation of *hIDO1* catalytic activity by L-Trp.

Kinetic mechanism of *hIDO1* catalysis

A good agreement among the experimentally-obtained $\text{Trp}k_{\text{cat}}/K_{\text{M}}$ and $\text{O}_2k_{\text{cat}}/K_{\text{M}}$ ratios and their computed values (modeled using the catalytic steps in Scheme 2), indicates that the reversibility of O₂ binding to ferrous *hIDO1* is impacting the catalytic efficiency of the enzyme at low O₂. The computed $\text{Trp}k_{\text{cat}}/K_{\text{M}}$ and $\text{O}_2k_{\text{cat}}/K_{\text{M}}$ ratios are represented by the solid lines in Fig. 3. A kinetic model that does not take into account the reversibility of O₂ binding in Step 1 (dashed lines in Fig. 3) overestimates the magnitude of $\text{O}_2k_{\text{cat}}/K_{\text{M}}$.

Even though Steps 1 and 2 in Scheme 2 are reversible, the existence of a rapid pre-equilibrium for binding of substrate to the free enzyme is not assured. A distinction between the steady-state and rapid pre-equilibrium mechanisms can be made by comparing the dissociation rate constants – k_{-1} and k_{-2} (Scheme 2), with the values of $\text{Trp}k_{\text{cat}}$ and O_2 . When the off rate constants for O₂ from $\text{Fe(III)}h\text{IDO1}\cdot\text{O}_2^{\bullet-}$ and L-Trp from $\text{Fe(II)}h\text{IDO1}\cdot\text{L-Trp}$ do not greatly exceed the values of $\text{Trp}k_{\text{cat}}$ and O_2k_{cat} , a steady-state mechanism is operational rather than a rapid pre-equilibrium one.^{64,65} Since the value of $k_{-2} = 501 \pm 10 \text{ s}^{-1}$ (Scheme 2)³⁵ is significantly greater than $\text{Trp}k_{\text{cat}}$ or O_2k_{cat} , the binding of L-Trp to ferrous *hIDO1* is expected to always be at equilibrium. However, the value of $k_{-1} = 6.8 \pm 1.8 \text{ s}^{-1}$ (Scheme 2) is comparable to $k_{\text{cat}} = 1.4 \pm 0.05 \text{ s}^{-1}$ at pH 8.0,²⁶ and smaller than $\text{Trp}k_{\text{cat}} = 8.3 \pm 0.5 \text{ s}^{-1}$ found in the current study,⁶⁶ supporting a steady-state regime for binding of O₂, to $\text{Fe(II)}h\text{IDO1}$.⁶⁴ Subsequently, the steady-state concentrations of O₂, $\text{Fe(II)}h\text{IDO1}$,

and $\text{Fe(III)}h\text{IDO1}\cdot\text{O}_2^{\bullet-}$ are not at equilibrium. Such nonequilibrium distribution of the active forms of the enzyme could lead to nonhyperbolic curves in plots of initial rates versus varied substrate concentration, if the pathways (from $\text{Fe(II)}h\text{IDO1}$ to the ternary complex in Scheme 2) differ significantly in rate.^{67,68} This unusual kinetic behavior highlights the fact that apparent enzyme inhibition does not have to involve more than one substrate binding site or more than one substrate molecule bound to the enzyme.⁶⁷ It is worth noting here that this effect vanishes in systems where all the active forms of the enzyme are at equilibrium.⁶⁷

When the concentration of one of the substrates for a bi-substrate enzyme is varied (substrate A), while the other substrate is fixed (substrate B), a general form of the steady-state initial rate expression is represented by Eq. 10.^{65,67}

$$\text{Initial Rate} = \frac{i[A]^2 + j[A]}{k + l[A]^2 + m[A]} \quad (10)$$

Here, $[A]$ is the concentration of varied substrate A, and i, j, k, l , and m are the products of the concentration of fixed substrate B and a combination of rate constants for various steps within the kinetic model.^{65,67} The exact form of expressions for i, j, k, l , and m as a function of the individual rate constants and $[B]$ could be quite complex. Ferdinand has demonstrated, by double differentiation of Eq. 10, that when $i \times m < j \times l$ and $i \times k < j \times m$, the initial rate curve (for varied substrate A at constant substrate B) shows an apparent enzyme inhibition at high levels of A.⁶⁷

L-Trp is a strong inhibitory substrate for $h\text{IDO1}$. Eq. 2 describes the dependence of the initial rate of $h\text{IDO1}$ catalysis on $[\text{L-Trp}]$. Eq. 10 can be recast as Eq. 2 by applying the following substitutions: $i = \text{Trp}k_{\text{cat}}/\text{Trp}K_{\text{SI}}$, $j = \text{Trp}k_{\text{cat}}$, $k = \text{Trp}K_{\text{M}}$, $l = 1/\text{Trp}K_{\text{SI}}$, and $m = 1$. Using the values of the steady-state kinetic parameters found by fitting the data, shown by red circles in Fig. 1 B, to Eq. 2 ($\text{Trp}k_{\text{cat}} = 8.3 \pm 0.5 \text{ s}^{-1}$, $\text{Trp}K_{\text{M}} = 19.0 \pm 2.7 \text{ }\mu\text{M}$, $\text{Trp}K_{\text{SI}} = 200 \pm 42 \text{ }\mu\text{M}$, and $\text{Trp}K'_{\text{SI}} = 1066 \pm 250 \text{ }\mu\text{M}$), we obtain the values of constants in Eq. 10: $i = 0.008 \pm 0.002 \text{ }\mu\text{M}^{-1}\text{s}^{-1}$, $j = 8.3 \pm 0.5 \text{ s}^{-1}$, $k = 19.0 \pm 2.7 \text{ }\mu\text{M}$, $l = 0.005 \pm 0.001 \text{ }\mu\text{M}^{-1}$, and $m = 1$. These constants satisfy the conditions of Ferdinand:⁶⁷ $i \times m = 0.008 \pm 0.002 \text{ }\mu\text{M}^{-1}\text{s}^{-1} < j \times l = 0.042 \pm 0.024 \text{ }\mu\text{M}^{-1}\text{s}^{-1}$ and $i \times k = 0.152 \pm 0.125 \text{ s}^{-1} < j \times m = 8.3 \pm 0.5 \text{ s}^{-1}$. Thus, the description of the inhibition of $h\text{IDO1}$ by L-Trp, in terms of only one binding site that accepts only one molecule of L-Trp during the turnover, does not contradict the kinetic model shown in Scheme 2.

Inhibition of $h\text{IDO1}$ by L-Trp

Three recent studies addressed the origin of L-Trp inhibition of $h\text{IDO1}$.^{22,23,35} The activity of the enzyme was proposed to be inhibited at high level of L-Trp due to a) the presence of a second inhibitory site,²² which binds L-Trp only weakly (hence the requirement for high L-Trp concentration), reducing the affinity of the catalytic site for L-Trp, b) the lowering of k_4 relative to k_1 (Scheme 2) upon binding of L-Trp to a single active site as a result of an increase in heme redox potential,²³ or c) the dead-end inhibition by L-Trp that reversibly binds to $\text{Fe(II)}h\text{IDO1}$, forming an inactive binary complex – $\text{Fe(II)}h\text{IDO1}\cdot\text{L-Trp}$.³⁵

A steady-state mechanistic model (Scheme 2), where one path from $Fe(II)hIDO1$ to the ternary complex is preferred, provides a rationale for inhibition of $hIDO1$ by L-Trp that involves only one binding site and one molecule of L-Trp.^{23,67,68} The magnitude of $^{Trp}K'_{SI}$, given by Eq. 11,⁶⁹ becomes a convenient reference point for analysis of the inhibitory effects of L-Trp.

$$^{Trp}K'_{SI} = \frac{1}{\alpha} \left(\frac{k_4 [O_2] + k_{-2}}{k_2} \right) + \frac{k_{-1}}{k_3} \quad (11)$$

Here, k_{-1} , k_2 , k_{-2} , k_3 , and k_4 are the individual rate constants shown in Scheme 2 and $\alpha = k_4/k_1$. When the concentration of L-Trp is approximately equal to $^{Trp}K'_{SI}$, the rates of O_2 depletion/NFK formation, via the top and the bottom pathways in Scheme 2, are equal. Eq. S37 in the Supporting Information illustrates this point.⁴¹ At $[L-Trp] \approx ^{Trp}K'_{SI}$, both pathways in Scheme 2 contribute equally to formation of the ternary complex – $hIDO1 \cdot O_2 \cdot L-Trp$, which disappears at twice the rate of individual pathways. For a fixed level of O_2 (such as air-saturation level), when $[L-Trp] \ll ^{Trp}K'_{SI}$, the top pathway in Scheme 2 dominates over the bottom route, because at low level of L-Trp, nearly irreversible addition of O_2 elevates $k_1[O_2]$ over $k_2[L-Trp]$, even though $k_2 > k_1$. As $[L-Trp]$ rises, the rate of the top pathway accelerates due to an increase in $k_3[L-Trp]$ $[^{Fe(III)}hIDO1 \cdot O_2 \cdot ^-]$ term, resulting in greater overall velocity. However, as concentration of L-Trp increases, so does the contribution of the slower pathway to the total rate, which leads to an apparent inhibition of the rate of O_2 depletion/NFK formation. The overall velocity passes through a maximum.^{67,68} In air-saturated buffer solution, maximum activity of $hIDO1$ is observed at $[L-Trp] \approx 73 \mu M$ (Fig. 1 A). At this level of L-Trp, the bottom path to the ternary complex in Scheme 2 contributes ~6% of the overall rate (see Eq. S35 in the Supporting Information). The rise in $[L-Trp]$ beyond $73 \mu M$ increases contribution of the bottom pathway, inhibiting the overall process. When $[L-Trp] \gg ^{Trp}K'_{SI}$, the initial rate reaches a plateau where the bottom pathway dominates (Scheme 2). For example, at 5 mM level of L-Trp, the contribution of this pathway is ~78%, and at 10 mM it reaches ~88%.⁴¹

Modeling inhibition of $hIDO1$ by L-Trp

The initial rate of catalysis, obtained by varying LTrp at a fixed O_2 level at air-saturation, is inhibited as L-Trp concentration increases (red circles in Fig. 1 B). We modeled L-Trp inhibition of $hIDO1$ using Eq. 12, which describes initial rate of oxygen consumption as a function of initial substrate concentrations and the individual rate constants for the catalytic steps in Scheme 2.⁷⁰

$$\frac{-\frac{d[O_2]}{dt}}{[hIDO1]_T} = \frac{1 - \frac{k_{-1}}{k_1[O_2]} \times \frac{k_1[O_2]}{k_3[L-Trp] + k_1} + \alpha \times \frac{k_2[L-Trp]}{k_4[O_2] + k_2}}{\frac{1}{k_1[O_2]} \left(1 + \frac{k_1[O_2]}{k_3[L-Trp] + k_1} + \frac{k_2[L-Trp]}{k_4[O_2] + k_2} + \frac{k_3[L-Trp]}{k_5} \times \frac{k_1[O_2]}{k_5[L-Trp] + k_1} + \frac{k_4[O_2]}{k_5} \times \frac{k_2[L-Trp]}{k_4[O_2] + k_2} \right)} \quad (12)$$

Here, k_1 , k_{-1} , k_2 , k_{-2} , k_3 , k_4 , and k_5 are the rate constants for the catalytic steps, shown in black in Scheme 2; $\alpha = k_4/k_1$. $[O_2]$ and $[L-Trp]$ are the initial concentrations of substrates.

We considered four models that differ in the magnitudes of k_2 and k_4 . The values of k_1 , k_{-1} , k_{-2} , k_3 , and k_5 were set as described in the section on modeling the dependence

of Varied k_{cat}/K_M on concentration of fixed substrate: $k_1 = 5.3 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$, $k_{-1} = 6.8 \text{ s}^{-1}$, $k_{-2} = 501 \text{ s}^{-1}$, $k_3 = 4.37 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$, and $k_5 = 8.3 \text{ s}^{-1}$. The results of modeling are presented in Fig. 5. Panels **A** and **B** show the outcomes for varied [L-Trp] and fixed $[\text{O}_2] = 230 \text{ } \mu\text{M}$ (which in our studies corresponds to air-saturation level of oxygen). Panel **C** visualizes the initial rates of oxygen consumption for varied O_2 at fixed $50.0 \text{ } \mu\text{M}$ L-Trp.

In all panels in Fig. 5, the solid purple line corresponds to a model with $k_2 = 1.25 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$ and $k_4 = 1.6 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ (Scheme 2). These values for the rate constants were introduced in the section on modeling the dependence of Varied k_{cat}/K_M on concentrations of fixed substrate. This model reproduces the initial rates for varied O_2 reasonably well (Fig. 5 **C**). It also accurately replicates the values of k_{cat} and K_M for varied L-Trp: $^{\text{Trp}}k_{\text{cat}} = 7.8 \text{ s}^{-1}$ and $^{\text{Trp}}K_M = 19 \text{ } \mu\text{M}$; however, the extent of *h*IDO1 inhibition by L-Trp, predicted by this model, is not as pronounced as the one observed experimentally. Here, $^{\text{Trp}}K_{\text{SI}} = 1260 \text{ } \mu\text{M}$ and $^{\text{Trp}}K'_{\text{SI}} = 1450 \text{ } \mu\text{M}$ (Fig. 5 **A** and **B**, solid purple line). Also, the modeled ratio of $^{\text{Trp}}K'_{\text{SI}}$ to $^{\text{Trp}}K_{\text{SI}}$ differs significantly from the one found experimentally. Further analysis shows that simply decreasing the value of k_4 does not significantly improve the reproduction of the experimentally-observed inhibition (Fig. 5, light blue dash-dot line). In this model, k_4 was lowered to $7.1 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$ – a value that replicates the experimental ratio of $^{\text{Trp}}K'_{\text{SI}}$ to $^{\text{Trp}}K_{\text{SI}}$, but not the magnitudes of these constants.⁷¹ Simultaneous raising of k_2 and lowering of k_4 is in better agreement with the experiment. A model, where $k_2 = 3.6 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ and $k_4 = 7.1 \times 10^3 \text{ M}^{-1} \text{ s}^{-1}$, gives $^{\text{Trp}}k_{\text{cat}} = 7.3 \text{ s}^{-1}$, $^{\text{Trp}}K_M = 17.4 \text{ } \mu\text{M}$, $^{\text{Trp}}K_{\text{SI}} = 199 \text{ } \mu\text{M}$, and $^{\text{Trp}}K'_{\text{SI}} = 1058 \text{ } \mu\text{M}$, in good agreement with experimental data (Fig. 5, blue long-dashed line).

Global fit of the data from O_2 consumption-based assays

To further improve the agreement between the kinetic model in Scheme 2 and results of our assays, we performed a global fit of the data in Fig. 2 using OriginPro 2015 (Origin) from OriginLab. Data points in Fig. 1, shown by red circles, were also included in the fit. Initial rate of L-Trp dioxygenation was fitted as a function of two independent variables (initial concentrations of O_2 and L-Trp) and seven parameters (rate constants for the catalytic steps in Scheme 2). The details of the 3D surface fitting procedure are given in the Supporting Information.⁴¹

An unconstrained fit, where all seven parameters are allowed to be optimized, results in very large standard errors for k_1 , k_{-1} , k_2 , and k_{-2} . Also, the magnitude of either k_2 or k_{-2} reaches a preset upper limit, where an increase in k_2 produces a compensating increase in k_{-2} , and vice versa. These observations suggest that parameters k_2 and k_{-2} are linked. These constants are the forward and reverse rate constants, respectively, for binding of L-Trp to free *h*IDO1. They are related by $^{\text{Trp}}K_d = k_{-2}/k_2$. Parameters k_1 and k_{-1} (the rate constants for binding and dissociation of O_2 , respectively, to and from ferrous *h*IDO1) are related by a similar expression: $k_{-1}/k_1 = ^{\text{O}_2}K_d$. Here, $^{\text{O}_2}K_d$ is an equilibrium constant for dissociation of O_2 from $^{\text{Fe(III)}}\text{hIDO1} \cdot \text{O}_2^{\bullet -}$. The connection between the parameters k_2 and k_{-2} (as well as k_1 and k_{-1}) is further supported by the strong dependency values of 1, computed for k_1 , k_{-1} , k_2 , and k_{-2} in Origin.

In order to avoid ambiguity due to an inherent correlation between k_1 and k_{-1} and between k_2 and k_{-2} , we fixed the values of k_{-1} and k_{-2} during further fitting. The value of k_{-2} was set equal to 501 s^{-1} , which is a measured rate constant for dissociation of L-Trp from $\text{Fe(II)}h\text{IDO1}\cdot\text{CO}\cdot\text{L-Trp}$;³⁵ k_{-1} was fixed at 4.84 s^{-1} – a value that was obtained from unconstrained fits and that is in close agreement with the experimental dissociation rate constant: $k_{-1} = 6.8 \pm 1.8 \text{ s}^{-1}$.²⁶ Global fitting with fixed k_{-1} and k_{-2} gives $k_1 = (1.83 \pm 0.64) \times 10^6 \text{ M}^{-1}\text{s}^{-1}$, $k_2 = (5.24 \pm 2.26) \times 10^7 \text{ M}^{-1}\text{s}^{-1}$, $k_3 = (5.05 \pm 0.20) \times 10^5 \text{ M}^{-1}\text{s}^{-1}$, $k_4 = (4.05 \pm 1.14) \times 10^3 \text{ M}^{-1}\text{s}^{-1}$, and $k_5 = 7.67 \pm 0.16 \text{ s}^{-1}$. These results are visualized in Fig. 6, where the calculated initial rates of O_2 consumption are plotted as solid lines together with the data from Fig. 2.

It is interesting to note here that global fitting gives the value of $^{\text{Trp}}K_d = 9.6 \pm 4.1 \mu\text{M}$ and $^{\text{O}_2}K_d = 2.6 \pm 1.2 \mu\text{M}$, regardless of the constraints or preset limits for k_1 , k_{-1} , k_2 and k_{-2} . The magnitude of $^{\text{Trp}}K_d$ for ferrous $h\text{IDO1}$ in the published literature ranges from $0.7 \pm 0.2 \mu\text{M}$ to $530 \pm 50 \mu\text{M}$,^{23,72} highlighting the difficulty of analyzing small optical changes in the absorption of heme moiety upon binding of L-Trp to the free enzyme.²³

As can be seen from the global fit, an accurate reproduction of experimental rates requires a kinetic model that features not only slow O_2 binding to $\text{Fe(II)}h\text{IDO1}\cdot\text{L-Trp}$, but also very fast binding of L-Trp to free $\text{Fe(II)}h\text{IDO1}$.

Conclusion

In the current work, we analyzed enzyme kinetics of human indoleamine 2,3-dioxygenase as a function of O_2 and L-Trp, at physiologically-relevant concentrations of both substrates. Using a new assay methodology for the study of $h\text{IDO1}$ catalysis, we performed quantitative analysis of the effects of O_2 concentration on the initial rates. We analyzed the data within a mechanistic model, where the total velocity is a sum of two individual pathways with significantly disparate rates. The kinetic protocol described here also provides a powerful and convenient means to characterize the action of therapeutic $h\text{IDO1}$ inhibitors in the physiological ranges of both substrates free of cofactor interference. This approach has the potential to enhance drug design capabilities for a range of human pathologies driven by $h\text{IDO1}$.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

We gratefully acknowledge Prof. A. Grant Mauk for the generous gift of $h\text{IDO1}$, cytochrome b_5 , and cytochrome b_5 reductase expression vectors and helpful discussions; Profs. Bruce E. Bowler and Stephen R. Sprang for the use of stopped-flow systems and other major biochemical equipment in their laboratories, and helpful discussions. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM103546 and the University of Montana. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Acquisition of the Bruker Microflex MALDI-ToF mass spectrometer was supported by the NSF CHE-1039814 award. Purchase of the AVIV Model 14 Spectrophotometer was supported by the NSF EPSCoR program under Grant # EPS-0701906 at the University of Montana.

ABBREVIATIONS

hIDO1	human indoleamine 2,3-dioxygenase isoform-1
TDO	tryptophan 2,3-dioxygenase
LTrp	L-tryptophan
1-Me-L-Trp	1-methyl-L-tryptophan
NFK	N-formyl-L-kynurenine
O₂	dioxygen
O₂^{•-}	superoxide anion
H₂O₂	hydrogen peroxide
NHM	norharmane (β-carboline)
IFN-γ	interferon-γ
NAD⁺	nicotinamide adenine dinucleotide
β-NADH	β-nicotinamide adenine dinucleotide hydride
Cu,Zn-SOD	copper-zinc superoxide dismutase
DNase I	deoxyribonuclease I
IPTG	isopropyl -D-1-thiogalactopyranoside
PMSF	phenylmethylsulfonyl fluoride
EDTA	ethylenediaminetetraacetic acid
MOPS	3-(N-morpholino)propanesulfonic acid
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
LRF MALDI-TOF	linear-reflectron matrix-assisted laser desorption/ionization time-of-flight mass spectrometer

REFERENCES

1. Voet, D.; Voet, JG. *Biochemistry, Volume One: Biomolecules, Mechanisms of Enzyme Action, and Metabolism*. 3rd Ed.. John Wiley & Sons; New York, NY: 2004. p. 1098
2. Ibid. :464.
3. Berger M, Gray JA, Roth BL. The expanded biology of serotonin. *Annu. Rev. Med.* 2009; 60:355–366. [PubMed: 19630576]
4. Bertazzo A, Ragazzi E, Biasiolo M, Costa CVL, Allegri G. Enzyme activities involved in tryptophan metabolism along the kynurenine pathway in rabbits. *Biochim. Biophys. Acta.* 2001; 1527:167–175. [PubMed: 11479034]
5. Wolf H. Studies on tryptophan metabolism in man: the effect of hormones and vitamin B₆ on urinary excretion of metabolites of the kynurenine pathway. *Scand. J. Clin. Lab. Invest.* 1974; 33(Suppl. 136):11–182. [PubMed: 4827753]
6. Sono M, Roach MP, Coulter ED, Dawson JH. Heme-containing oxygenases. *Chem. Rev.* 1996; 96:2841–2887. [PubMed: 11848843]
7. Poulos TL. Heme enzyme structure and function. *Chem. Rev.* 2014; 114:3919–3962. [PubMed: 24400737]

8. Mellor A. Indoleamine 2,3-dioxygenase and regulation of T-cell immunity. *Biochem. Biophys. Res. Commun.* 2005; 338:20–24. [PubMed: 16157293]
9. Opitz CA, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature.* 2011; 478:197–203. [PubMed: 21976023]
10. Vazquez S, Aquilina JA, Jamie JF, Sheil MM, Truscott RJW. Novel protein modification by kynurenine in human lenses. *J. Biol. Chem.* 2002; 277:4867–4873. [PubMed: 11726659]
11. Hood BD, Garner B, Truscott RJW. Human lens coloration and aging: evidence for crystallin modification by the major ultraviolet filter, 3-hydroxy-kynurenine O- β -D-glucoside. *J. Biol. Chem.* 1999; 274:32547–32550. [PubMed: 10551806]
12. Wirleitner B, Neutrauer G, Schroecksnadel K, Frick B, Fuchs D. Interferon- γ -induced conversion of tryptophan: immunologic and neuropsychiatric aspects. *Curr. Med. Chem.* 2003; 10:1581–1591. [PubMed: 12871129]
13. Carlin JM, Borden EC, Sondel PM, Byrne GI. Biologic response modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. *J. Immunol.* 1987; 139:2414–2418. [PubMed: 2443564]
14. Roth A, König P, van Zandbergen G, Klinger M, Hellwig-Bürgel T, Däubener W, Bohlmann MK, Rupp J. Hypoxia abrogates antichlamydial properties of IFN- γ in human fallopian tube cells in vitro and ex vivo. *Proc. Natl. Acad. Sci. U.S.A.* 2010; 107:19502–19507. [PubMed: 20974954]
15. Herbert A, Ng H, Jessup W, Kockx M, Cartland S, Thomas SR, Hogg PJ, Wargon O. Hypoxia regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. *British J. Dermatology.* 2011; 164:308–315.
16. Schmidt SK, Ebel S, Keil E, Woite C, Ernst JF, Benzin AE, Rupp J, Däubener W. Regulation of IDO activity by oxygen supply: inhibitory effects on antimicrobial and immunoregulatory functions. *PLoS ONE.* 2013; 8(5):e63301. doi:10.1371/journal.pone.0063301. [PubMed: 23675474]
17. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. *J. Cell. Mol. Med.* 2011; 15:1239–1253. [PubMed: 21251211]
18. Yamamoto S, Hayaishi O. Tryptophan pyrrolase of rabbit intestine D- and L- tryptophan-cleaving enzyme or enzymes. *J. Biol. Chem.* 1967; 242:5260–5266. [PubMed: 6065097]
19. Sono M, Taniguchi T, Watanabe Y, Hayaishi O. Indoleamine 2,3-dioxygenase: equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes. *J. Biol. Chem.* 1980; 255:1339–1345. [PubMed: 7354029]
20. Sono M. The roles of superoxide anion and methylene blue in the reductive activation of indoleamine 2,3-dioxygenase by ascorbic acid or by xanthine oxidase/hypoxanthine. *J. Biol. Chem.* 1989; 264:1616–1622. [PubMed: 2536368]
21. Sono M. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. *Biochemistry.* 1989; 28:5400–5407. [PubMed: 2789077]
22. Lu C, Yeh S-R. Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase. *J. Am. Chem. Soc.* 2009; 131:12866–12867. [PubMed: 19737010]
23. Efimov I, Basran J, Sun X, Chauhan N, Chapman SK, Mowat CG, Raven EL. The mechanism of substrate inhibition in human indoleamine 2,3-dioxygenase. *J. Am. Chem. Soc.* 2012; 134:3034–3041. [PubMed: 22299628]
24. Taniguchi T, Sono M, Hirata F, Hayaishi O, Tamura M, Hayashi K, Iizuka T, Ishimura Y. Indoleamine 2,3-dioxygenase kinetic studies on the binding of superoxide anion and molecular oxygen to enzyme. *J. Biol. Chem.* 1979; 254:3288–3294. [PubMed: 218967]
25. Sono M. Spectroscopic and equilibrium properties of the indoleamine 2,3-dioxygenase–tryptophan–O₂ ternary complex and of analogous enzyme derivatives. Tryptophan binding to ferrous enzyme adducts with dioxygen, nitric oxide, and carbon monoxide. *Biochemistry.* 1986; 25:6089–6097. [PubMed: 3098285]

26. Chauhan N, Basran J, Efimov I, Svistunenko DA, Seward HE, Moody PCE, Raven EL. The role of serine 167 in human indoleamine 2,3-dioxygenase: a comparison with tryptophan 2,3-dioxygenase. *Biochemistry*. 2008; 47:4761–4769. [PubMed: 18370410]
27. Lewis-Ballester A, Batabyal D, Egawa T, Lu C, Lin Y, Marti MA, Capece L, Estrin DA, Yeh S-R. Evidence for a ferryl intermediate in a heme-based dioxygenase. *Proc. Natl. Acad. Sci. U.S.A.* 2009; 106:17371–17376. [PubMed: 19805032]
28. Davydov RM, Chauhan N, Thackray SJ, Anderson JLR, Papadopoulou ND, Mowat CG, Chapman SK, Raven EL, Hoffman BM. Probing the ternary complexes of indoleamine and tryptophan 2,3-dioxygenases by cryoreduction EPR and ENDOR spectroscopy. *J. Am. Chem. Soc.* 2010; 132:5494–5500. [PubMed: 20353179]
29. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. *Nature Med.* 2005; 11:312–319. [PubMed: 15711557]
30. Novitskiy SV, Moses HL. Turn off the IDO: will clinical trials be successful? *Cancer Discovery*. 2012; 2:673–675. [PubMed: 22886661]
31. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. *J. Exp. Med.* 2013; 210:1389–1402. [PubMed: 23752227]
32. Here, we designate the ferrous hIDO1 adduct with O₂ as $\text{Fe}^{\text{(III)}}\text{hIDO1}\cdot\text{O}_2^{\bullet-}$ to indicate that it exhibits $\text{Fe}^{\text{(III)}}\text{--O}_2^{\bullet-}$ rather than $\text{Fe}^{\text{(II)}}\text{--O}_2$ character, based on recent resonance Raman studies.²⁷
33. Yanagisawa S, Horitani M, Sugimoto H, Shiro Y, Okada N, Ogura T. Resonance Raman study on the oxygenated and the ferryl-oxo species of indoleamine 2,3-dioxygenase during catalytic turnover. *Faraday Discuss.* 2011; 148:239–247. [PubMed: 21322487]
34. Yanagisawa S, Hara M, Sugimoto H, Shiro Y, Ogura T. Resonance Raman study on indoleamine 2,3-dioxygenase: control of reactivity by substrate-binding. *Chemical Physics*. 2013; 419:178–183.
35. Weber B, Nickel E, Horn M, Nienhaus K, Nienhaus GU. Substrate inhibition in human indoleamine 2,3-dioxygenase. *J. Phys. Chem. Lett.* 2014; 5:756–761.
36. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. *Clin. Chem.* 1997; 43:2424–2426. [PubMed: 9439467]
37. Madras BK, Cohen EL, Messing R, Munro HN, Wurtman RJ. Relevance of free tryptophan in serum to tissue tryptophan concentrations. *Metabolism*. 1974; 23:1107–1116. [PubMed: 4427559]
38. Rosell FI, Kuo HH, Mauk AG. NADH oxidase activity of indoleamine 2,3-dioxygenase. *J. Biol. Chem.* 2011; 286:29273–29283. [PubMed: 21690092]
39. Lloyd E, Ferrer JC, Funk WD, Mauk MR, Mauk AG. Recombinant human erythrocyte cytochrome b₅. *Biochemistry*. 1994; 33:11432–11437. [PubMed: 7918357]
40. Trepanier, LA.; Bajad, SU.; Kurian, JR. Evaluation of the cytochrome b₅/cytochrome b₅ reductase pathway in Current Protocols in Toxicology. Costa, LG.; Davila, JC.; Lawrence, DA.; Reed, DJ., editors. John Wiley & Sons; 2005. p. 4.16.1-4.16.17.doi:10.1002/0471140856.tx0416s24
41. See Supporting Information.
42. YSI, Inc. The Dissolved Oxygen Handbook: a Practical Guide to Dissolved Oxygen Measurements. 2009:46.
43. Grant Mauk A. personal communication.
44. Papadopoulou ND, Mewies M, McLean KJ, Seward HE, Svistunenko DA, Munro AW, Raven EL. Redox and spectroscopic properties of human indoleamine 2,3-dioxygenase and a His303Ala variant: implications for catalysis. *Biochemistry*. 2005; 44:14318–14328. [PubMed: 16245948]
45. Dawson, RMC.; Elliott, DC.; Elliott, WH.; Jones, KM. Data for Biochemical Research. 3rd Ed.. Oxford University Press; USA: 1989. p. 122
46. Ishimura Y, Nozaki M, Hayaishi O, Nakamura T, Tamura M, Yamazaki I. The oxygenated form of L-tryptophan 2,3-dioxygenase as reaction intermediate. *J. Biol. Chem.* 1970; 245:3593–3602. [PubMed: 5470825]
47. Sono M, Cady SG. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. *Biochemistry*. 1989; 28:5392–5399. [PubMed: 2789076]

48. Vottero E, Mitchell DA, Page MJ, MacGillivray RT, Sadowski IJ, Roberge M, Mauk AG. Cytochrome b₅ is a major reductant in vivo of human indoleamine 2,3-dioxygenase expressed in yeast. *FEBS Lett.* 2006; 580:2265–2268. [PubMed: 16574111]
49. Maghzal GJ, Thomas SR, Hunt NH, Stocker R. Cytochrome b₅, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. *J. Biol. Chem.* 2008; 283:12014–12025. [PubMed: 18299324]
50. Yanagisawa S, Yotsuya K, Hashiwaki Y, Horitani M, Sugimoto H, Shiro Y, Appelman EH, Ogura T. Identification of the Fe–O₂ and the Fe=O heme species for indoleamine 2,3-dioxygenase during catalytic turnover. *Chem. Lett.* 2010; 39:36–37.
51. Pearson JT, Siu S, Meininger DP, Wienkers LC, Rock DA. In vitro modulation of cytochrome P450 reductase supported indoleamine 2,3-dioxygenase activity by allosteric effectors cytochrome b₅ and methylene blue. *Biochemistry.* 2010; 49:2647–2656. [PubMed: 20178337]
52. Cleland, WW. *Steady State Kinetics in The Enzymes*, Volume II, Kinetics and Mechanism. Boyer, PD., editor. Academic Press; New York, NY: 1970. p. 1
53. The derivation of Eq. 2 is shown in the Supporting Information, see Eq. S13.⁴¹
54. Fromm, HJ. *Initial Rate Enzyme Kinetics*. Springer-Verlag; Berlin, Germany: 1975. p. 49
55. Lu C, Yeh S-R. Spectroscopic studies of ligand and substrate binding to human indoleamine 2,3-dioxygenase. *Biochemistry.* 2010; 49:5028–5034. [PubMed: 20476772]
56. The derivation of Eq. 6 is presented in the Supporting Information, see Eq. S20.⁴¹
57. For the derivation of Eq. 4 see Eq. S18 in the Supporting Information.⁴¹
58. The derivation of Eqs 4 through 9 is shown in the Supporting Information, see Eq. S18, S19, S20, S29, S30, and S33, respectively.⁴¹
59. Cady SG, Sono M. 1-Methyl-DL-tryptophan, β-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and β-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. *Arch. Biochem. Biophys.* 1991; 291:326–333. [PubMed: 1952947]
60. Chauhan N, Thackray SJ, Rafice SA, Eaton G, Lee M, Efimov I, Basran J, Jenkins PR, Mowat CG, Chapman SK, Raven EL. Reassessment of the reaction mechanism in the heme dioxygenases. *J. Am. Chem. Soc.* 2009; 131:4186–4187. [PubMed: 19275153]
61. Fromm, HJ. *Initial Rate Enzyme Kinetics*. Springer-Verlag; Berlin, Germany: 1975. p. 94
62. Cook, PF.; Cleland, WW. *Enzyme Kinetics and Mechanism*. Garland Science; New York, NY: 2007. p. 157
63. Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. *Biochem. J.* 1974; 137:143–144. [PubMed: 4206907]
64. Cook, PF.; Cleland, WW. *Enzyme Kinetics and Mechanism*. Garland Science; New York, NY: 2007. p. 76
65. Segel, IH. *Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems*. John Wiley & Sons; New York, NY: 1975. p. 646
66. The magnitude of k_{-1} (Scheme 2) is expected to be pH-independent between 6.5 and 8.0, because in $\text{Fe(III)}_{\text{hIDO}}\text{1}\cdot\text{O}_2^{\bullet-}$ the frequency of $\nu_{\text{Fe-O}_2}$ mode is pH-independent in the same range.³³
67. Ferdinand W. The interpretation of non-hyperbolic rate curves for two-substrate enzyme: a possible mechanism for phosphofructokinase. *Biochem. J.* 1966; 98:278–283. [PubMed: 4223117]
68. Segel, IH. *Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems*. John Wiley & Sons; New York, NY: 1975. p. 657
69. For the derivation of Eq. 11 see Eq. S22 in the Supporting Information.⁴¹
70. For the origin of Eq. 12 see the derivation of Eq. S9 in the Supporting Information.⁴¹
71. Obtained by dividing Eq. S22 by Eq. S21 and solving the resulting ratio for k_4 .⁴¹
72. Sugimoto H, Oda S.-i. Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O₂ incorporation by a heme-containing dioxygenase. *Proc. Natl. Acad. Sci. U.S.A.* 2006; 103:2611–2616. [PubMed: 16477023]

Highlights

- Activity of human indoleamine 2,3-dioxygenase (*hIDO1*) at low O₂ is measured.
- Bi-substrate enzyme kinetics of *hIDO1* is investigated.
- Initial rates are measured as a function of concentration of both substrates.
- A quantitative analysis of O₂ concentration effects on initial rate is performed.
- The mechanism of substrate inhibition of *hIDO1* by L-tryptophan is discussed.

Scheme 1.
Reaction catalyzed by IDO.

Adapted from ref. 6. The heme cofactor is shown as a parallelogram with nitrogen atoms at

the corners; L-Trp, bound in the catalytic site of *h*IDO1, is indicated by an oval. Enzyme activation and the steps leading to deactivation of *h*IDO1 via autoxidation are shown in light blue. The catalytic steps are depicted in black.

Fig. 1.

Initial rates of *hIDO1* catalysis as a function of L-Trp concentration at 25.0 °C. Conditions: 20 mM air-saturated MOPS buffer at pH 7.0, [O₂] = 230 μM.⁴² The left panel (A) shows a narrower window of L-Trp concentrations (3 μM • [L-Trp] • 450 μM) and the right panel (B) displays the full range of [L-Trp] used in the study (3 μM • [L-Trp] • 5000 μM). Data represented by red circles were determined by O₂ depletion-based assays, [*hIDO1*]_T = 219 nM. The error bars reflect ±σ from 3-5 individual experiments. The blue diamonds are from the NFK formation-based assays, where [*hIDO1*]_T = 262 nM with 20 mM ascorbate, 10 μM methylene blue, and 100 U/ml catalase. The error bars reflect ±σ for 8-10 individual experiments. The solid lines are the best fits of the data to Eq. 1, and the dashed lines are the best fits to Eq. 2.

Fig. 2.

Initial rates of *hIDO1* catalysis, measured by monitoring O₂ depletion, in 20 mM MOPS buffer at pH 7.0 and 25.0 °C; [*hIDO1*]_T = 188 nM, with the exception of the data shown by red circles where [*hIDO1*]_T = 219 nM. **A:** fixed O₂ levels are indicated in the plot; L-Trp was varied from 8.33 μM to 50.0 μM . The solid lines show the best fits of the data to Eq. 1. **B:** fixed L-Trp levels are indicated in the plot; O₂ was varied from 11.5 μM to 230 μM ; for 50.0 μM L-Trp, O₂ concentrations were changed from 4.6 μM to 348 μM . The solid lines are the best fits of the data to Eq. 3, except for 20.0 μM and 50.0 μM L-Trp where the Michaelis-Menten equation was used. The error bars reflect $\pm\sigma$ for 3-5 separate experiments.

Fig. 3.

Dependence of the $\text{Varied } k_{\text{cat}}/K_{\text{M}}$ ratios on the initial concentration of fixed substrate. The data are from Tables 1 and 2. The red circles and red lines correspond to $\text{Trp } k_{\text{cat}}/K_{\text{M}}$ vs. fixed $[\text{O}_2]$, while the blue diamonds and blue lines depict $\text{O}_2 k_{\text{cat}}/K_{\text{M}}$ vs. fixed $[\text{L-Trp}]$. The error bars reflect propagated experimental uncertainty in the values of k_{cat} and K_{M} . The solid and dashed lines show the $\text{Varied } k_{\text{cat}}/K_{\text{M}}$ ratios, modeled using Eq. 6 (red) and 9 (blue). The dashed lines correspond to the model with $k_{-1} = 0 \text{ s}^{-1}$.

Scheme 3.

Substrate analogs of L-Trp and O₂, respectively, used in *h*IDO1 inhibition studies.

Fig. 4.

Double-reciprocal plots, $1/\text{Initial Rate}$ vs. $1/[\text{L-Trp}]$ and $1/\text{Initial Rate}$ vs. $1/[\text{O}_2]$, showing *hIDO1* inhibition patterns for 1-Me-L-Trp (**A** and **C**) and norharmane (**B** and **D**); the error bars reflect $\pm\sigma$ for 3-5 individual experiments; the solid lines are the best linear fits of the data, extrapolated to axis limits; fixed μM inhibitor concentrations are shown on the lines. Here, $[\text{hIDO1}]_{\text{T}}$ ranges from 160 nM to 188 nM. **A** and **B**: varied $[\text{L-Trp}]$, fixed $[\text{O}_2] = 46.1 \mu\text{M}$. **C** and **D**: varied $[\text{O}_2]$, fixed $[\text{L-Trp}] = 16.7 \mu\text{M}$.

Fig. 5.

Results of modeling the inhibition of *hIDO1* by L-Trp. Red circles show the experimental data. **A**: varied L-Trp at fixed air-saturation level of $[O_2] = 230 \mu M$, **B**: expansion of **A** from zero to $240 \mu M$ L-Trp, **C**: varied O_2 at fixed $[L-Trp] = 50.0 \mu M$; the solid red line shows the best fit of the experimental data to Eq. 2 (**A** and **B**) and the Michaelis-Menten equation (**C**). The purple solid line corresponds to a model with $k_2 = 1.25 \times 10^6 M^{-1}s^{-1}$ and $k_4 = 1.6 \times 10^5 M^{-1}s^{-1}$; light blue dash-dot line matches the model with $k_2 = 1.25 \times 10^6 M^{-1}s^{-1}$ and $k_4 = 7.1 \times 10^3 M^{-1}s^{-1}$; green dashed line: $k_2 = 8.42 \times 10^6 M^{-1}s^{-1}$ and $k_4 = 7.1 \times 10^3 M^{-1}s^{-1}$; blue long-dashed line: $k_2 = 3.6 \times 10^7 M^{-1}s^{-1}$ and $k_4 = 7.1 \times 10^3 M^{-1}s^{-1}$.

Fig. 6.

Results of the global fit with fixed k_{-1} and k_{-2} (solid lines) overlaying the experimental data from Fig. 2 (colored symbols). The micromolar levels of the fixed substrate are displayed on the lines. **A:** varied L-Trp, fixed O₂; (●) correspond to 230 μM O₂, (▼) – 115 μM O₂, (▲) – 80.6 μM O₂, (■) – 56.7 μM O₂, (▼) – 43.8 μM O₂, and (▲) – 34.5 μM O₂. **B:** varied O₂, fixed L-Trp; (●) correspond to 50.0 μM L-Trp, (▼) – 20.0 μM L-Trp, (▲) – 16.7 μM L-Trp, (■) – 13.3 μM L-Trp, (▼) – 10.0 μM L-Trp, and (▲) – 8.33 μM L-Trp.

Table 1

Steady-state kinetic parameters – $\text{Trp}k_{\text{cat}}$, $\text{Trp}K_{\text{M}}$, $\text{Trp}K_{\text{SI}}$, and $\text{Trp}k_{\text{cat}}/K_{\text{M}}$ ratios, obtained by the best fit of the data in Fig. 2 A to Eq. 1.

$[\text{O}_2]$, μM	$\text{Trp}k_{\text{cat}}$, s^{-1}	$\text{Trp}K_{\text{M}}$, μM	$\text{Trp}k_{\text{cat}}/K_{\text{M}}$, $^a \mu\text{M}^{-1}\text{s}^{-1}$	$\text{Trp}K_{\text{SI}}$, μM
34.5	7.1 ± 0.9	21.1 ± 3.9	0.33 ± 0.08	59 ± 16
43.8	8.5 ± 1.1	24.0 ± 4.7	0.35 ± 0.08	75 ± 24
57.6	8.5 ± 1.5	20.7 ± 5.4	0.41 ± 0.13	95 ± 45
80.6	8.9 ± 1.8	20.1 ± 6.2	0.44 ± 0.16	100 ± 57
115	9.7 ± 2.7	23.4 ± 9.6	0.41 ± 0.20	104 ± 83
230	10.3 ± 1.5	25.6 ± 5.6	0.40 ± 0.11	124 ± 56
230 ^b	8.3 ± 0.5	19.0 ± 2.7	0.44 ± 0.07	200 ± 42

^a Here, $\text{Trp}k_{\text{cat}}/K_{\text{M}} = \text{Trp}k_{\text{cat}}/\text{Trp}K_{\text{M}}$.

^b From the best fit of the data, shown by red circles in Fig. 1 B, to Eq. 2.

Table 2

Steady-state kinetic parameters – O_2k_{cat} , O_2K_M , O_2K_{SI} , and O_2k_{cat}/K_M ratios, derived from the best fit of the data in Fig. 2 **B** to Eq. 3.

[L-Trp], μM	O_2k_{cat} , s^{-1}	O_2K_M , μM	O_2k_{cat}/K_M , $\text{a } \mu\text{M}^{-1}\text{s}^{-1}$	O_2K_{SI} , μM
8.33	3.7 ± 0.4	23.7 ± 6.4	0.15 ± 0.04	468 ± 175
10.0	4.2 ± 0.4	24.0 ± 6.2	0.17 ± 0.05	572 ± 234
13.3	4.1 ± 0.2	14.2 ± 2.3	0.28 ± 0.05	2270 ± 1635
16.7	4.4 ± 0.1	11.5 ± 1.2	0.38 ± 0.04	4101 ± 2974
20.0 ^b	4.8 ± 0.1	14.0 ± 1.2	0.34 ± 0.03	----
50.0 ^b	5.8 ± 0.1	18.6 ± 0.6	0.31 ± 0.01	----

^a Here, $O_2k_{\text{cat}}/K_M = O_2k_{\text{cat}}/O_2K_M$.

^b From the best fit to the Michaelis-Menten eq.

Table 3

Steady-state constants – $\text{Trp}k_{\text{cat}}$ and $\text{Trp}K_{\text{M}}$, and $\text{Trp}k_{\text{cat}}/K_{\text{M}}$ ratios, calculated using Eq. 4, 5, and 6, respectively.

[O ₂], μM	$\text{Trp}k_{\text{cat}}$, s^{-1}	$\text{Trp}K_{\text{M}}$, μM	$\text{Trp}k_{\text{cat}}/K_{\text{M}}$, $\text{a } \mu\text{M}^{-1}\text{s}^{-1}$
34.5	5.6	17.6	0.32
43.8	6.1	17.8	0.34
57.6	6.5	18.0	0.36
80.6	6.9	18.2	0.38
115	7.3	18.3	0.40
230	7.7	18.5	0.42

^aHere, $\text{Trp}k_{\text{cat}}/K_{\text{M}} = \text{Trp}k_{\text{cat}}/\text{Trp}K_{\text{M}}$.

Table 4

Steady-state constants – $^{O_2}k_{\text{cat}}$ and $^{O_2}K_M$, and $^{O_2}k_{\text{cat}}/K_M$ ratios, calculated using Eq. 7, 8, and 9, respectively.

[L-Trp], μM	$^{O_2}k_{\text{cat}}$, s^{-1}	$^{O_2}K_M$, μM	$^{O_2}k_{\text{cat}}/K_M$, $^a \mu\text{M}^{-1}\text{s}^{-1}$
8.33	2.5	13.7	0.19
10.0	2.9	13.9	0.21
13.3	3.4	14.2	0.24
16.7	3.9	14.4	0.27
20.0	4.3	14.6	0.29
50.0	6.0	16.0	0.38

^aHere, $^{O_2}k_{\text{cat}}/K_M = ^{O_2}k_{\text{cat}}/^{O_2}K_M$.